Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Talis Biomedical Corporation (TLIS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 50 K | -57,064,000 | 29.22 M | 98.34 M | 77.68 M |
| 2022 | 308 K | -96,609,000 | 42.55 M | 169.29 M | 133.28 M |
| 2021 | 183 K | -218,568,000 | 31.85 M | 265.83 M | 236.12 M |
| 2020 | 471 K | -137,790,000 | 306.98 M | 198.41 M | 188.72 M |
| 2019 | 1.81 M | -21,604,000 | 46.87 M | 25.73 M | 24.11 M |